Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Champions Biotechnology has entered into a royalty agreement with Concordia Pharmaceuticals, a developer of cancer therapies, for the use of Salirasib, Concordia's novel compound for the treatment of cancer, in combination with another targeted drug.
Subscribe to our email newsletter
Under the terms of the agreement, Champions will use its Biomerk Tumorgraft preclinical platform to evaluate a combination therapy indication for Salirasib, a Ras antagonist.
This agreement modifies an earlier preclinical services agreement between the companies and now provides royalty rights for Champions Biotechnology for a specific combination therapy indication for Salirasib in the event that required milestones are achieved.
Doug Burkett, president of Champions Biotechnology, said: “This is a further example of our ability to leverage our preclinical technology to create high potential for Champions Biotechnology while enhancing the value of drugs for pharmaceutical and biotechnology companies.
“Based on our predictive Biomerk Tumorgraft platform, it is our intent to build a low attrition pipeline of cancer drugs that we own, co-own or to which we have royalty rights. We are very pleased to enter into this promising arrangement with Concordia Pharmaceuticals.”